See more : Burin Gold Corp. (BURG.V) Income Statement Analysis – Financial Results
Complete financial analysis of PainReform Ltd. (PRFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PainReform Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Nahar Industrial Enterprises Limited (NAHARINDUS.NS) Income Statement Analysis – Financial Results
- Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. (EDD) Income Statement Analysis – Financial Results
- American Coastal Insurance Corporation (ACIC) Income Statement Analysis – Financial Results
- Western Forest Products Inc. (WEF.TO) Income Statement Analysis – Financial Results
- PlaySide Studios Limited (PLY.AX) Income Statement Analysis – Financial Results
PainReform Ltd. (PRFX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.painreform.com
About PainReform Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 0.00 | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 15.00K | 15.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 |
Gross Profit | -15.00K | 71.00K | -7.00K | 0.00 | -1.00K | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 82.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 6.04M | 4.42M | 2.86M | 354.00K | 136.00K | 223.00K | 504.00K |
General & Administrative | 3.48M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
Selling & Marketing | 66.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 3.55M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
Cost & Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
Interest Income | 406.00K | 160.00K | 0.00 | 1.05K | 588.00 | 0.00 | 245.00K |
Interest Expense | 384.00K | 61.00K | 10.00K | 987.00K | 541.00K | 324.00K | 0.00 |
Depreciation & Amortization | 15.00K | 15.00K | 7.00K | 1.00K | 1.00K | 500.00K | 880.00K |
EBITDA | -9.57M | -8.85M | -7.20M | -1.67M | -688.00K | 0.00 | -1.21M |
EBITDA Ratio | 0.00% | -10,124.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -9.58M | -8.87M | -7.21M | -1.67M | -689.00K | -500.00K | -880.00K |
Operating Income Ratio | 0.00% | -10,312.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 248.00K | 86.00K | -32.00K | -2.16M | -590.00K | -328.00K | -242.00K |
Income Before Tax | -9.34M | -8.78M | -7.24M | -3.83M | -1.28M | -828.00K | -1.12M |
Income Before Tax Ratio | 0.00% | -10,212.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 8.00K | 9.00K | 6.00K | 220.00K | 541.00K | 4.00K | -242.00K |
Net Income | -9.34M | -8.79M | -7.25M | -4.05M | -1.82M | -828.00K | -2.09M |
Net Income Ratio | 0.00% | -10,223.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -42.86 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.67 |
EPS Diluted | -42.83 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.25 |
Weighted Avg Shares Out | 218.00K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.00K |
Weighted Avg Shares Out (Dil) | 218.15K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.66K |
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
PainReform Provides Business Update for the First Quarter of 2024
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
Source: https://incomestatements.info
Category: Stock Reports